← Eichor
Study identifier: NCT07556718 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease

Condition: Quiescent Crohn's Disease (CD)  ·  Sponsor: University of Michigan

PhasePhase 2
Planned participants100
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Many individuals with Crohn's disease continue to experience abdominal pain, bloating, or bowel habit changes even when their inflammation is controlled. Amitriptyline is a medication commonly used at low doses to treat irritable bowel syndrome (IBS) and abdominal pain. This study will assess whether amitriptyline is safe and reduces those ongoing GI symptoms in adults with Crohn's disease in remission.

This description comes directly from the study's public registry record.

Talk to the study team

Charlie Bourque Jr.  ·  (734) 615-3911  ·  cabjr@med.umich.edu

Allen A. Lee, MD, MS  ·  (734) 936-9454  ·  allenlee@med.umich.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of MichiganAnn Arbor, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07556718